PPARA and pulmonary arterial hypertension: Moreover, prostacyclin treatment improves pulmonary artery hypertension (PAH) patients, suggesting that the 5-HT2BR-prostacyclin/PPAR-ß/δ coupling could also be involved in PAH [38].